Protein Kinase C - CiteSeerX

Supplemental Material can be found at: http://www.jbc.org/cgi/content/full/M800250200/DC1 THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 17, pp. 11794 –11806, April 25, 2008 © 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.

Protein Kinase C-⑀ Regulates Sphingosine 1-Phosphate-mediated Migration of Human Lung Endothelial Cells through Activation of Phospholipase D2, Protein Kinase C-␨, and Rac1*□ S

Received for publication, January 10, 2008, and in revised form, February 21, 2008 Published, JBC Papers in Press, February 22, 2008, DOI 10.1074/jbc.M800250200

Irina Gorshkova‡, Donghong He‡, Evgeny Berdyshev‡, Peter Usatuyk‡, Michael Burns‡, Satish Kalari‡, Yutong Zhao‡, Srikanth Pendyala‡, Joe G. N. Garcia‡, Nigel J. Pyne§, David N. Brindley¶1, and Viswanathan Natarajan‡2 From the ‡Department of Medicine, University of Chicago, Chicago, Illinois 60637, §Department of Physiology and Pharmacology, University of Strathclyde, Glasgow G4 ONR, United Kingdom, and ¶Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2S2, Canada

Sphingosine 1-phosphate (S1P)3 is a naturally occurring bioactive sphingolipid that elicits multiple cellular responses such

* This work was supported by National Institutes of Health Grant HL RO1 79396 (to V. N.) and Canadian Institute of Health Research Grant MOP 81137 (to D. N. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. □ S The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1– 4 and Table 1. 1 Recipient of a Medical Scientist Award from the Alberta Heritage Foundation for Medical Research. 2 To whom correspondence should be addressed: Dept. of Medicine, The University of Chicago, CIS Bldg., Rm. W408B, 929 East 57th St., Chicago, IL 60637. Tel.: 773-834-2638; Fax: 773-834-2687; E-mail: vnataraj@medicine. bsd.uchicago.edu. 3 The abbreviations used are: S1P, sphingosine 1-phosphate; S1P1, S1P receptor; EC, endothelial cell; HPAEC, human pulmonary artery EC; PLC, phos-

11794 JOURNAL OF BIOLOGICAL CHEMISTRY

as differentiation, proliferation, survival, and angiogenesis (1–5). S1P acts as an intracellular second messenger. Extracellular S1P also activates intracellular signaling pathways through ligation to a family of G-protein-coupled S1P receptors, S1P1–5 (previously known as endothelial differentiation gene receptors) (6). The S1P-Rs are differentially expressed in different cell types and are coupled to Gi, Gq, or G12/13 (7–9). Coupling of S1P to S1P1 via Gi activates Rac and Rho (2, 10) and stimulates cell proliferation (4), cortical actin formation (11), assembly of adherens junction, and angiogenesis (2). Binding of S1P to S1P3 induces signaling through Gq or G13 to activate Rho (2, 10, 12), promotes the formation of stress fibers and adherens junctions (2), stimulates phospholipase D (PLD) (13), and activates phospholipase C/intracellular Ca2⫹/protein kinase C (PKC) pathways (7). Ligation of S1P to S1P1 also initiates cross-talk with other receptors, especially growth factor receptors including those for epidermal growth factor (EGF), platelet-derived growth factor, and vascular endothelial growth factor (14). The functional platelet-derived growth factor (PDGF)-␤/S1P1 signaling complex was postulated to be involved in regulating migration of mouse embryonic fibroblasts in response to PDGF (15). Furthermore, S1P binding to S1P2 inhibits cell migration via Gq or G13 (9, 12, 16) and activates adenylate cyclase (17) and mitogen-activated protein kinases (MAPKs) (18). There are few studies related to S1P signaling via S1P4 and S1P5; however, these receptors may be involved in change in cell shape (19) and neurite retraction (20). In addition to the well described vascular effects of S1P (21), in non-vascular tissues S1P exhibits proinflammatory effects such as increased interleukin-6/-8 secretion in airway epithelial (22) and ovarian cancer cells (23). In the vasculature, S1P is a key regulator of vascular maturation and angiogenesis under physiological and pathological conditions. Angiogenesis, or new blood vessel formation, is pholipase C; PLD, phospholipase D; PKC, protein kinase C; EGF, epidermal growth factor; MAPK, mitogen-activated protein kinase; PA, phosphatidic acid; LPA, lysophosphatidic acid; dn, dominant negative; EGM, endothelial growth medium; EBM, endothelial basal medium; ECIS, electrical cell substrate impedance sensing; PTx, pertussis toxin; RT, reverse transcription; siRNA, small interfering RNA; BSA, bovine serum albumin; m.o.i., multiplicity of infection; PBt, phosphatidylbutanol; TBST, Tris-buffered saline Tween; FBS, fetal bovine serum; PBD, p21 binding domain.

VOLUME 283 • NUMBER 17 • APRIL 25, 2008

Downloaded from www.jbc.org at University of Chicago Library on June 11, 2008

The signaling pathways by which sphingosine 1-phosphate (S1P) potently stimulates endothelial cell migration and angiogenesis are not yet fully defined. We, therefore, investigated the role of protein kinase C (PKC) isoforms, phospholipase D (PLD), and Rac in S1P-induced migration of human pulmonary artery endothelial cells (HPAECs). S1P-induced migration was sensitive to S1P1 small interfering RNA (siRNA) and pertussis toxin, demonstrating coupling of S1P1 to Gi. Overexpression of dominant negative (dn) PKC-⑀ or -␨, but not PKC-␣ or -␦, blocked S1P-induced migration. Although S1P activated both PLD1 and PLD2, S1P-induced migration was attenuated by knocking down PLD2 or expressing dnPLD2 but not PLD1. Blocking PKC-⑀, but not PKC-␨, activity attenuated S1P-mediated PLD stimulation, demonstrating that PKC-⑀, but not PKC-␨, was upstream of PLD. Transfection of HPAECs with dnRac1 or Rac1 siRNA attenuated S1P-induced migration. Furthermore, transfection with PLD2 siRNA, infection of HPAECs with dnPKC-␨, or treatment with myristoylated PKC-␨ peptide inhibitor abrogated S1P-induced Rac1 activation. These results establish that S1P signals through S1P1 and Gi to activate PKC-⑀ and, subsequently, a PLD2-PKC-␨-Rac1 cascade. Activation of this pathway is necessary to stimulate the migration of lung endothelial cells, a key component of the angiogenic process.

Regulation of S1P-induced Endothelial Cell Migration

EXPERIMENTAL PROCEDURES Materials—S1P, dihydrosphingosine 1-phosphate, and ceramide 1-phosphate (8:0) were obtained from Avanti Polar Lipids (Alabaster, AL). LPA, dioleoylglycerol, and brain phosphatidylserine were purchased from Sigma-Aldrich. Ceramide1-phosphate (18:1) was a generous gift from Dr. C. E. Chalfant (Richmond, VA). Pertussis toxin was purchased from Calbiochem. SB649146 was from GlaxoSmithKline. Myelin basic protein was obtained from Upstate Biotechnology (Lake Placid, NY). Myristoylated PKC-␨ peptide inhibitor was purchased from BIOMOL Research Labs Inc. (Plymouth Meeting, PA). AntiAPRIL 25, 2008 • VOLUME 283 • NUMBER 17

PKC-␨ antibody, PKC-⑀ peptide inhibitor, scrambled siRNA, and target siRNA for PLD1, PLD2, and Rac1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). AntiS1P1 antibody was obtained from Affinity BioReagents (Golden, CO), anti-S1P2, anti-S1P3, anti-S1P4, and anti-S1P5 antibodies were purchased from Exalpha Biological Inc. (Maynard, MA), anti-PKC␣ and anti-PKC-␦ antibodies were from BD Transduction Laboratories, and anti-Rac1 antibody was from BD Biosciences Pharmingen. Anti-PKC⑀ and anti-phospho-PKC-⑀(Ser-729) antibodies were purchased from Upstate Biotechnology; anti-phospho-PKC-␨/␭(Thr-410/403) was obtained from Cell Signaling Technology Inc. (Danvers, MA). Anti-phosphoserine antibody was from Zymed Laboratories Inc. (San Francisco, CA). Internal and N-terminal antibodies for PLD1 and PLD2 were purchased from BIOSOURCE International Inc. (Camarillo, CA), and anti-PLD2 antibody was kindly provided by Dr. Sylvain Bourgoin (Quebec, PQ, Canada). Anti-␤-actin antibody was from Sigma. S1P1 siRNA was from Dharmacon (Lafayette, CO). Rac1 activation assay kit was obtained from Upstate (Temecula, CA). Lysis buffer was purchased from Cell Signaling Technology Inc. (Danvers, MA). Protease inhibitor mixture tablets (EDTA-free Complete) were from Roche Diagnostics. Aprotinin and phosphatase inhibitor mixture 1 were from Sigma-Aldrich. Ad5CA dominant negative (dn)-PKC-␣, dnPKC-␭, dnPKC-␦, dnPKC-⑀, and dnPKC␨ were kindly provided by Dr. Motoi Ohba from Institute of Molecular Oncology (Showa University, Japan). Cell Culture—HPAECs (passage number 3) were purchased from Cambrex Inc. (Walkersville, MD) and cultured in complete endothelial growth medium (EGM)-2 medium (46). The cells (passage number 5– 8) in 35- or 100-mm dishes or glass coverslips were used for all the experiments. Endothelial Cell Migration—HPAEC were cultured in 12- or 6-well plates to ⬃95% confluence and then starved in the serum-free EGM-2 medium for 1–3 h or in EBM-2 medium containing 0.1% FBS for 18 –24 h. The cell monolayer was wounded by scratching across the monolayer with a 10-␮l standard sterile pipette tip. The scratched monolayer was rinsed twice with serum-free medium to remove cell debris and incubated with varying concentrations of S1P. The area (⬃1 cm2 total) in a scratched area was recorded at 0 and 16 –24 h using a Hamamatsu digital camera connected to the Nikon Eclipse TE2000-S microscope with ⫻10 objective and MetaVue software (Universal Imaging Corp.). Images were analyzed by the Image J software. The effect of S1P and other agents on cell migration/wound healing was quantified by calculating the percentage of the free area not occupied by cells compared with an area of the initial wound that was defined as closure of wounded area. Electrical Cell Substrate Impedance Sensing (ECIS) Assay— HPAEC were cultured in 8-well ECIS electrode arrays (8W1E, Applied Biophysics, NY) to ⬃95% confluence and starved in the serum-free EBM-2 medium for 1–3 h. An elevated field (3 V at 40,000 Hz for 10 s) was applied to wound the cells on the electrode. Either complete medium or medium containing S1P (100 –1000 nM) was added, and wound healing was monitored for 10 –20 h by measuring the transendothelial electrical resistJOURNAL OF BIOLOGICAL CHEMISTRY

11795


critical for normal embryonic vascular development and in tumor metastasis. Although targeted deletion of S1P2 or S1P3 in mice has no adverse effect on embryogenesis, deletion of S1P1 caused failure of vascular development leading to a massive hemorrhage and embryonic lethality between E12.5 and E14.5 (24). Endothelial cell (EC) migration is an essential component of angiogenesis that is regulated by growth factors, bioactive molecules, and intracellular signaling (25). Among the various agonists, S1P has emerged as a potent angiogenic, and vascular maturation factor and considerable evidence exists for S1Pinduced endothelial cell proliferation (4), migration (26 –28), chemotaxis (29), and endothelial cell remodeling (30). Based on a number of studies using inhibitors, siRNA, dn mutants, or genetically engineered mice, it is becoming evident that several signaling pathways including Rho/Rac, phosphatidylinositol 3-kinase, Akt, MAPKs, PKC, and changes in intracellular Ca2⫹ are involved in S1P-induced EC migration (3, 7, 8, 12, 31). We recently demonstrated that PLD activation by S1P regulates ERK1/2 activation (31) and interleukin-8 secretion in human bronchial epithelial cells (22, 32). Furthermore, involvement of lipid phosphate phosphatase-1 in regulating lysophosphatidic acid (LPA)-induced phosphatidate (PA) generation and fibroblast migration suggests a role for PLD2 in fibroblast migration, wound healing, and tumor metastasis (33). PA is a bioactive lipid, and its generation by PLD activation represents an important signaling cascade involved in the regulation of cellular responses including proliferation (34) and cytoskeletal reorganization (35). PA also serves as an immediate precursor of LPA or diacylglycerol, which is an endogenous activator of several PKC isoforms (36). PA itself stimulates the PKC-␨ isoform (37, 38), phosphatidylinositol 4-kinase (39 – 41), phospholipase C-␥ (42, 43), and sphingosine kinase-1 (44), and it inhibits protein phosphatase-1 (45). In ECs, very little is known regarding the role of S1P-induced PLD activation and generation of PA in cell migration, wound healing, and angiogenesis. Therefore, in the present study we investigated the role of S1P on human pulmonary artery endothelial cell (HPAEC) and established how the activation of the PKC isoform(s) is involved in upstream and downstream signaling of PLD1 and/or PLD2 in relation to the stimulation of cell migration. Our results show that physiologically relevant concentrations of S1P markedly stimulated HPAEC migration, which was sensitive to pertussis toxin (PTx) and a S1P1 antagonist. Furthermore, evidence is provided for the role of PKC-⑀, but not PKC-␨, in S1P-induced PLD activation and the PLD2mediated stimulation of PKC-␨, Rac1, and cell migration.



FIGURE 1. S1P stimulates migration of HPAECs in a scratch assay in vitro. HPAECs grown to ⬃95% confluence in 35-mm dishes were starved for 3 h in 0.1% FBS in EBM-2 without growth factors, and monolayers were scratched and challenged with medium containing 0.1% BSA or 1.0 ␮M of S1P, dihydrosphingosine 1-phosphate (DHS1P), ceramide1-P (C8:0), ceramide1-P (C18: 1), and LPA for 16 h. In A and B, phase contrast images captured at 0 and 16 h after the scratch are shown. C shows the migration of cells into a “wound” that was scratched and exposed to various agonists previously. The values are the mean ⫾ S.E. for three independent experiments, and each experiment was carried out in triplicate.

and 1 mM dithiothreitol) and resuspended in 100 ␮l of kinase buffer. The activity of PKC was measured in 100 ␮l of kinase buffer containing 25 ␮g of myelin basic protein as an exogenous substrate to which 10 ␮M ATP, 2 ␮g of dioleoylglycerol, 12 ␮g of phosphatidylserine, and 20 – 40 ␮l of immunoprecipitate were added. Incubations were carried out for 10 min at 30 °C and terminated by the addition of 20 ␮l of Laemmli sample buffer. Samples were then boiled for 5 min and analyzed for phosphorylation of myelin basic protein by Western blotting with antiphosphoserine antibody. VOLUME 283 • NUMBER 17 • APRIL 25, 2008


ance using the ECIS equipment (11, 47). In all experiments S1P was complexed with 0.1% BSA. Infection of HPAECs with Adenoviral Vectors—cDNA for wild type and catalytically inactive mutants of PLD1, PLD2, and dominant negative Rac1 were subcloned into the pShuttleCMV vector (32). The recombinant plasmid was linearized and transfected into HEK293 cells to generate replication-defective adenovirus. Generation of purified virus (1010 plaque-forming units/ml) was carried out by the University of Iowa Gene Transfer Vector Core. Purified adenovirus (1–10 m.o.i. or plaqueforming units/cell) in complete EGM-2 medium was added to HPAECs grown to ⬃80% confluence in 6-well plates or 60- or 100-mm dishes. After 24 h, the virus-containing medium was replaced with complete EGM-2 medium. Vector control or infected cells were subjected to scratch and wound-healing ECIS assays, and immunoprecipitates or cell lysates were analyzed by Western blotting. Measurement of PLD Activation by S1P—HPAECs in 35-mm dishes were labeled with [32P]orthophosphate (5 ␮Ci/ml) in phosphate-free DMEM for 18 –24 h at 37 °C in 5% CO2 and 95% air. Cells were then challenged with EBM-2 medium alone or EBM-2 containing S1P plus 0.1% BSA in the presence of 0.1% 1-butanol (22, 32). In some experiments incubations were also carried out in the presence of 0.1% 3-butanol that served as additional controls. Incubations were terminated by the addition of 1 ml of methanol:HCl (100:1 v/v), cells were scraped into glass tubes, and lipids were extracted by the addition of 1 ml of methanol:HCl (100:1 v/v), 2 ml of chloroform, and 0.8 ml of 1 N HCl. [32P]Phosphatidylbutanol (PBt), formed as a result of PLD activation and transphosphatidylation of [32P]PA to 1-butanol, but not butan-3-ol, was separated from the total lipid extract by thin layer chromatography on 1% potassium oxalate plates with the upper phase of ethyl acetate:2,2,4-trimethyl pentane:glacial acetic acid:water (65:10:15:50 v/v) as the developing solvent system (22, 32). Unlabeled PBt was added as carrier during separation of labeled lipids that were visualized by exposure to iodine vapor. Radioactivity associated with PBt was quantified by liquid scintillation counting, and all values were normalized to 106 dpm in total lipid extract. [32P]PBt formed in control and S1P-challenged samples was expressed as dpm/dish or percent control. Measurement of PKC-⑀ and PKC-␨ Activation—HPAECs were cultured in 100-mm dishes to ⬃95% confluence, starved in EBM-2 medium containing 0.1% FBS for 3 h, stimulated with S1P for 5–10 min, washed with cold phosphate-buffered saline containing 1 mM vanadate, and lysed with 500 ␮l of lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na3VO4, 1 mM dithiothreitol, 1 ␮g/ml leupeptin, 1 ␮g/ml aprotinin, and protease inhibitors from EDTA-free Complete tablets (Roche Applied Science). Cells were subsequently sonicated twice for 15 s and then centrifuged at 10,000 ⫻ g for 15 min. Supernatants were collected and incubated overnight with polyclonal antiPKC-⑀ or anti-PKC-␨ antibody at 4 °C. The immunoprecipitates were washed 3 times with lysis buffer and 2 times with kinase buffer (20 mM HEPES (pH 7.4), 25 mM ␤-glycerophosphate, 10 mM MgCl2, 1 mM EGTA, 1 mM sodium orthovanadate,


APRIL 25, 2008 • VOLUME 283 • NUMBER 17

JOURNAL OF BIOLOGICAL CHEMISTRY

11797


lysates (20 –30 ␮g protein) were separated on 10% or 4 –20% SDSPAGE, transferred to polyvinylidene difluoride membranes, and blocked in TBST containing 5% BSA before incubation with primary antibody (1:1000 dilution) overnight. After blocking, washing, and incubation with appropriate secondary antibody, blots were developed using an ECL chemiluminescence kit. Western blots were scanned by densitometry, and integrated density of pixels in identified areas was quantified using ImageQuant Version 5.2 software (GE Healthcare). Immunofluorescence Microscopy— HPAECs grown on coverslips (18 mm) or chamber slides were starved for 3 h in EBM-2 containing 0.1% FBS before treatment with S1P (100 –1000 nM) for 5– 60 min. Cells were fixed in 3.7% paraformaldehyde in phosphate-buffered saline for 10 min, washed 3 times with FIGURE 2. S1P-stimulated migration of HPAECs is dependent on S1P1. HPAECs (⬃95% confluence) were phosphate-buffered saline, pertreated by SB649146 (10 ␮M) for 1 h before scratching or wounding. S1P (1.0 ␮M) conjugated to 0.1% BSA was meabilized with methanol for 4 added to scratched (A) or wounded (B) cells in wound healing assays. In A, the average area by which the gap between the ECs closed over 16 h after the addition of S1P was determined. The values are the mean ⫾ S.E. for min at ⫺20 °C, blocked with 2% three independent experiments in triplicates. B shows the changes in transendothelial electrical resistance BSA in TBST, incubated for 1 h (ohms) in vehicle and S1P-treated (1.0 ␮M) cells after wounding. The values are the mean ⫾ S.E. for four with appropriate primary antiindependent experiments. In C, HPAECs (⬃50% confluence) were transfected with either scrambled siRNA or S1P1 siRNA (100 nM, 72 h) before scratching the cells for migration assay. Scratched cells were challenged with body (1:200 dilution), washed with EBM-2 medium alone or EBM-2 containing S1P (1.0 ␮M) for 16 h, and total RNA was analyzed for the mRNA TBST, and stained for 1 h with secexpression of S1P1 and S1P4 by real time RT-PCR and normalized to 18 S RNA. The values are averages of three ondary antibody (1:200 dilution) independent experiments. The inset shows a representative Western blot (WB) for S1P1. D shows the average area by which the gap between the endothelial cells closed over a 16-h period after exposure to either EBM-2 in TBST containing 2% BSA. Cells medium alone or EBM-2 containing S1P (1.0 ␮M). The values are the mean ⫾ S.E. for three independent were examined using a Nikon experiments. Eclipse TE2000-S immunofluorescence microscope and a HamamRac1 Activation Assay—HPAECs were cultured in 100-mm atsu digital camera with ⫻60 oil immersion objective and dishes to ⬃50% confluence for siRNA transfection or to ⬃95% Meta Vue software. RNA Isolation and Real Time RT-PCR—Total RNA was isoconfluence for adenoviral infection or inhibitor treatment. Cells were starved in EBM-2 medium containing 0.1% FBS for lated from HPAECs grown on 35-mm dishes using TRIzol威 3 h before stimulation with S1P for 2–15 min, cell lysates were reagent according to the manufacturer’s instruction. iQ SYBR subjected to immunoprecipitation with PAK-1 PBD, and Rac1 Green Supermix was used to do the real time measurements activation was evaluated using the Rac1 Activation assay kit as using iCycler by Bio-Rad. 18 S (sense, 5⬘-GTAACCCGTTGAACCCCATT-3⬘, and antisense, 5⬘-CCATCCAATCGGper the manufacturer’s instruction (Upstate). Western Blot Analysis—HPAECs were cultured in 6-well TAGTAGCG-3⬘) was used as a housekeeping gene to normalplates or 60-mm dishes to ⬃95% confluence and starved for 3 h ize expression. The reaction mixture consisted of 0.3 ␮g of total in EBM-2 medium containing 0.1% FBS. Cells were stimulated RNA (target gene) or 0.03 ␮g of total RNA (18 S rRNA), 12.5 ␮l with S1P (100 –1000 nM) for 5– 60 min, washed with phos- of iQ SYBR Green, 2 ␮l of cDNA, 1.5 ␮M target primers, or 1 ␮M phate-buffered saline, and lysed with 100 –300 ␮l of lysis buffer 18 S rRNA primers in a total volume of 25 ␮l. For all samples containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM reverse transcription was carried out at 25 °C for 5 min followed Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyro- by cycling to 42 °C for 30 min and 85 °C for 5 min with iScript phosphate, 1 mM ␤-glycerophosphate, 1 mM Na3VO4, 1 ␮g/ml cDNA synthesis kit. Amplicon expression in each sample was leupeptin, 1 ␮g/ml aprotinin, and protease inhibitors from normalized to its 18 S rRNA content. The relative abundance of EDTA-free Complete tablets (Roche Applied Science). Cell target mRNA in each sample was calculated as 2 raised to the lysates were cleared by centrifugation at 10,000 ⫻ g for 10 min negative of its threshold cycle value times 106 after being norand boiled with the Laemmli sample buffer for 5 min. Cell malized to the abundance of its corresponding 18 S rRNA


(housekeeping gene) (2⫺(primer threshold cycle)2⫺(18 S threshold cycle) ⫻ 106). All primers were designed by inspection of the genes of interest using Primer 3 software. Negative controls consisting of reaction mixtures containing all components except target RNA were included with each of the RT-PCR runs. To verify that amplified products were derived from mRNA and did not represent genomic DNA contamination, representative PCR mixtures for each gene were run in the absence of the RT enzyme after first being cycled to 95 °C for 15 min. In the absence of reverse transcription, no PCR products were observed. siRNA Transfection—HPAECs grown to ⬃50% confluence in 6-well plates or chamber slides were transfected with Gene Silencer威 (Gene Therapy System, Inc. San Diego, CA)-transfecting agent containing scrambled siRNA (50 –100 nM) or siRNA for target proteins (50 –100 nM) in serum-free EBM-2 medium according to the manufacturer’s recommendation. To optimize conditions for efficient transfection, HPAECs were transfected with Fl-Luciferase GL2 Duplex siRNA (target sequence. 5⬘-CGTACGCGGAATACTTCGA-3⬘, Dharmacon) as a positive control. After 3 h of transfection, 1 ml of fresh complete EGM-2 medium containing 10% FBS was added, and cells were cultured for additional 72 h and analyzed for mRNA levels by real time PCR or protein expression by Western blotting. Scrambled siRNA control or siRNA-transfected cells were subjected to scratch or wound healing experiments as described earlier. Statistical Analysis—Analysis of variance and Student-Newman-Keul’s test were used to compare the means of two or more different treatment groups. The level of significance was set to p ⬍ 0.05 unless otherwise stated. Results are expressed as mean ⫾ S.E.


FIGURE 4. Effect of overexpression of dominant negative PKC isoforms on S1P-induced migration of HPAECs. HPAEC (⬃85% confluence) were infected with adenoviral constructs of vector control or dnPKC-␣, -␦, -⑀, and -␨ isoforms for 24 h before “scratch” migration assay with and without S1P. In A HPAECs were infected with vector control or dnPKC-␣, -␦, -⑀, and -␨ isoforms (5 m.o.i.) for 24 h. The cells were scratched for the migration assay and challenged with EBM-2 medium alone or medium containing S1P (1.0 ␮M) in the presence of 0.1% BSA. The migration of cells was recorded by imaging at 0 and 16 h after scratch, and the average area by which the gap between the ECs closed over 16 h was determined. The values are the mean ⫾ S.E. for three independent experiments in triplicate and expressed as % control. *, significantly different from cells challenged with EBM-2 without S1P (p ⬍ 0.05); **, significantly different from cells stimulated with S1P (p ⬍ 0.05); ***, significantly different from cells treated with S1P (p ⬍ 0.01). In B, HPAECs were pretreated with PKC-⑀ peptide inhibitor (10 ␮M) or myristoylated PKC-␨ peptide inhibitor (10 ␮M) for 1 h before scratch assay with S1P, and cell migration was determined 16 h post-S1P (1.0 ␮M) challenge. The values are the mean ⫾ S.E. for three independent experiments in triplicate and expressed as % of control. *, significantly different from cells challenged with EBM-2 without S1P (p ⬍ 0.01); **, significantly different from cells stimulated with S1P (p ⬍ 0.05); ***, significantly different from cells exposed to S1P (p ⬍ 0.001).

RESULTS S1P, but Not LPA or Ceramide-1-phosphate, Stimulates Migration of HPAECs—To determine the role of exogenous S1P, dihydro-S1P, LPA, or ceramide 1-phosphate in EC motility, we employed two complimentary assays of wound closure that measure the non-directional, chemokinetic movement. Among the four lipid phosphates tested, S1P was the most potent stimulator of HPAEC migration in both the scratch and ECIS wound healing assays (Fig. 1, A–C). Furthermore, the wound closure was dose-dependent, with ⬃50% of the wounded area remaining free of cells after exposure to S1P (10 nM) for 16 h as compared with ⬃25% with 100 nM S1P (suppleVOLUME 283 • NUMBER 17 • APRIL 25, 2008


FIGURE 3. S1P activates PKC-␦, -⑀, and -␨ isoforms in HPAEC. HPAECs (⬃95% confluence) were treated with EBM-2 alone or EBM-2 containing S1P (1 ␮M) for 10 min, and cell lysates were subjected to immunoprecipitation (IP) with PKC-␣, -␦, -⑀, and -␨ isoform-specific antibodies as described under “Experimental Procedures.” In A, PKC activity was performed in the immunoprecipitates using myelin basic protein (MBP) as a substrate. Phosphorylation of myelin basic protein was determined by Western blotting with anti-phosphoserine antibody. Shown is a representative blot from three independent experiments. B shows quantification of the data from A, and values were normalized to total PKC isoform in the immunoprecipitate. The values are the mean ⫾ S.E. for three independent experiments.




11799


predominant receptor expressed in HPAECs and the involvement of Gi in transducing signals from S1P ligation to its receptors in cell migration. To obtain evidence that S1P1 is involved in S1P-induced cell migration and wound healing, we tested the ability of SB649146, which reduces constitutively active S1P1 and blocks S1P binding (48), on S1P-mediated cell motility. Pretreatment of HPAECs with SB649146 (10 ␮M) for 1 h reduced S1P-induced migration (Fig. 2A). Furthermore, SB649146 decreased the basal migration of cells in the absence of added S1P (Fig. 2A). A similar effect of SB649146 on S1Pinduced EC migration was observed in ECIS wound healing assay (Fig. 2B). To further characterize the role of S1P1 in S1P-mediated cell migration, HPAECs were transfected with S1P1 siRNA (100 nM) for 72 h, cells were wounded and challenged with FIGURE 5. Overexpression of K758R PLD2 mutant, but not K898R PLD1, attenuates S1P-induced migra- S1P (1 ␮M) for 16 h, and migration tion and wound healing of HPAECs. HPAECs (⬃80% confluence in 35-mm dishes) (A and B) or ⬃80% conflu- was evaluated. S1P1 siRNA effecence in gold ECIS electrodes) (C and D) were infected with adenoviral vectors containing cDNA for hPLD1 or tively down-regulated mRNA exmPLD2 mutant (10 m.o.i.) for 24 h. Cells were scratched (A and B) or wounded on the gold electrodes (C and D) as described under “Experimental Procedures” before S1P (1.0 ␮M) challenge for 16 h. The migration of cells pression of S1P1, but not S1P4, and was recorded by imaging at 0 and 16 h after scratch, and the average area by which the gap between the ECs protein expression of S1P (⬃60%) 1 closed over 16 h was determined (A and B). The values are the mean ⫾ S.E. for three independent experiments (Fig. 2C). Furthermore, the S1P-inin triplicates. Measurement of transendothelial electrical resistance using an ECIS system for 16 h after wounding the cells on the gold electrode, and exposure to 1.0 ␮M S1P was carried out (C and D). Values are the mean ⫾ duced migration of HPAECs was S.E. for three independent experiments in triplicate, and resistance was expressed in ohms. N.S., not significant. almost completely attenuated by knockdown of S1P1 (Fig. 2D). These mental Fig. 1, A–D). Our results on S1P-induced cell migration combined results establish the role for S1P1 in regulating S1Pare in agreement with a previous report (26). In contrast, LPA induced cell migration in HPAECs. and ceramide 1-phosphate did not stimulate cell migration sigInvolvement of PKC-⑀ and PKC-␨ in S1P-induced HPAEC nificantly in HPAECs, and this finding differs from an earlier Migration—It has been reported that PKC-␣ regulates the report on LPA-induced migration of bovine aortic and human action of S1P on EC motility (49); however, the PKC isoform(s) umbilical vein ECs (27). involved in S1P-induced migration has not been well defined. S1P1 Is Required for S1P-induced HPAEC Migration—S1P Analysis of total cell lysates by Western blotting revealed that exerts its action through G-protein-coupled S1P1–5 receptors PKC-␣, -␦, -⑀, and -␨ are the predominant isoforms present in (7–9). To determine which S1P receptor subtype(s) is involved HPAECs (results not shown). To investigate which isoforms of in S1P-induced cell migration, we first examined the expression PKC are activated by S1P, serum-deprived HPAECs were chalof S1P receptors by real time RT-PCR using specific primers lenged with S1P (1 ␮M), and activation of PKC isoforms was derived from human sequences (supplemental Table 1). Anal- determined by immunoprecipitating each PKC isoform sepayses of total RNA by real time RT-PCR showed that all the five rately and measuring the activity. Immunoprecipitates of S1P receptors were expressed in the order of S1P1 ⬎ S1P3 ⬎ PKC-␦, -⑀, and -␨, but not PKC-␣, from S1P-challenged cells S1P2 ⬎ S1P4 ⬎ S1P5 (supplemental Fig. 1A). Complementing exhibited enhanced serine phosphorylation of myelin basic the mRNA expression profile, Western blot analyses showed protein (Fig. 3). Next, we investigated the role of PKC-␣, -␦, -⑀, S1P1 to be abundantly expressed in HPAECs (supplemental Fig. and -␨ isoforms in S1P-stimulated HPAEC migration by infect2B). Because S1P receptors are coupled to heterotrimeric G ing cells with dominant negative isoforms of each PKC. Infecproteins (7–9), we examined the effect of treating HPAECs with tion of HPAECs with adenoviral vectors encoding for 100 ng/ml of PTx for 3 h. This significantly blocked basal as well dnPKC-␣, -␦, -⑀, and -␨ (5 m.o.i.) for 24 h resulted in overexas S1P-mediated cell migration and wound healing (supple- pression of each protein (⬃5-fold) (results not shown). Overmental Fig. 2, C and D). These results suggest that S1P1 is the expression of dnPKC-⑀, and -␨ isoforms (5 m.o.i.), but not





D). However, overexpression of the catalytically inactive mutants of hPLD1-K898R (vehicle, 766 ⫾ 171 dpm; S1P, 1272 ⫾ 61 dpm) and mPLD2-K758R (vehicle, 1140 ⫾ 136 dpm; S1P, 1543 ⫾ 116 dpm) partially blocked S1P-induced [32P]PBt formation without affecting the basal activity (supplemental Fig. 3, C and D). To examine the role of S1P1 in S1P-induced PLD activation, we investigated the effects of SB 649146 and PTx on S1P-induced PLD activity. SB649146, attenuated PLD activation by S1P (vehicle, 1267 ⫾ 123 dpm; S1P, 4330 ⫾ 286 dpm; SB649146 ⫾ vehicle, 1229 ⫾ FIGURE 6. Effect of PLD2 siRNA on expression of PLD1 and PLD2 in HPAEC and on S1P-induced migration 92 dpm; SB649146 ⫾ S1P, 2640 ⫾ of HPAECs. HPAECs grown to ⬃60% confluence in 35-mm dishes or glass coverslips were transfected with Gene Silencer reagent plus scrambled (sc) siRNA or Gene Silencer reagent plus PLD2 siRNA (50 nM) for 72 h as 568 dpm) showing the involvement described under “Experimental Procedures.” In A, total RNA was isolated from control and PLD2 siRNA-trans- of S1P receptor (supplemental Fig. 1 fected cells, and real time PCR was performed in a Light Cycler using SYBR Green QuantiTect. In B, cell lysates (20 ␮g of total protein) were subjected to SDS-PAGE on 10% precast Tris glycine gels and Western blotted with 3E). Also, S1P activation of anti-PLD2 antibody as described under “Experimental Procedures.” The Western blot (WB) is representative of transphosphorylation of [32P]PA to three independent experiments. The cells were scratched after 72 h of post-transfection for the migration assay 1-butanol was PTx-sensitive (vehiand challenged with EBM-2 medium alone or medium containing S1P (1.0 ␮M) in the presence of 0.1% BSA. The migration of cells was recorded by imaging at 0 and 16 h after scratch, and the average area by which the gap cle, 881 ⫾ 146 dpm; S1P, 1889 ⫾ 77 between the ECs closed over 16 h was determined. The values are the mean ⫾ S.E. for three independent dpm; PTx⫹ vehicle, 810 ⫾ 169 dpm; experiments. PTx ⫾ S1P, 1177 ⫾ 146 dpm), indicating coupling of S1P1 to Gi (supPKC-␣ and -␦ isoforms, significantly reduced S1P-induced cell plemental Fig. 3F). This supports the hypothesis that S1P-inmigration compared with vector-infected cells (Fig. 4A). Fur- duced activation of PLD is via S1P1 coupled to Gi in HPAECs. thermore, the effect of dnPKC-⑀ and -␨ overexpression on S1PPLD2, but Not PLD1, Is Involved in S1P-induced HPAEC induced wound closure was dependent on multiplicity of infec- Migration—To further characterize the role of PLD1 and PLD2 tion with maximum inhibition observed at 10 m.o.i. (data not in S1P-induced cell migration and wound healing, HPAECs shown). The role of PKC-⑀ and -␨ in cell migration was also were infected with the adenoviral constructs (10 m.o.i.) encodtested using specific peptide inhibitors and is shown in Fig. 4B. ing catalytically inactive hPLD1-K898R and mPLD2-K758R Pretreatment of HPAECs with either PKC-⑀ peptide inhibitor mutants for 24 h before S1P challenge. Overexpression of (10 ␮M) or myristoylated PKC-␨ peptide (10 ␮M) attenuated mPLD2-K758R, but not hPLD1-K798R, attenuated S1P-inS1P-induced cell migration. These results establish that S1P- duced cell migration and wound healing, as evidenced by induced wound closure is dependent on activation of PKC-⑀ scratch and ECIS assay (Fig. 5, A–D). The role of PLD2 in cell migration was further investigated by knocking down PLD2 and -␨ isoforms in HPAECs. S1P Activates PLD1 and PLD2 in HPAECs—PLD is activated expression with PLD2 siRNA. HPAECs were transfected with by S1P in bronchial epithelial cells and fibroblasts (22), and we PLD2 siRNA (50 and 100 nM) for 48 h, and the efficacy of the have previously showed that PLD2 regulated the LPA-mediated siRNA was determined by real time RT-PCR for mRNA levels migration of rat fibroblasts (33). Here, we investigated the role and Western blotting for protein. Transfection of HPAECs of PLD isoforms in S1P-induced cell migration. Cell lysates with siRNA for PLD2 specifically blocked the mRNA expresfrom HPAECs infected with adenoviral vectors encoding wild sion of PLD2 without affecting PLD1 expression (Fig. 6A). Furtype and catalytically inactive mutants of hPLD1 and mPLD2 thermore, treatment with PLD2 siRNA (50 nM) for 48 h atten(10 m.o.i.) for 24 h showed increased protein expression (sup- uated S1P-induced cell migration in the scratch assay as plemental Fig. 3, A and B). The functional significance of wild compared with cells transfected with scrambled siRNA (Fig. type and mutants of hPLD1 and mPLD2 overexpression was 6B). In parallel experiments, transfection of cells with PLD1 tested by quantifying the accumulation of [32P]PBt in the pres- siRNA had no effect on S1P-induced migration (results not ence of 1-butanol (32). In HPAECs infected with wild type shown). These results demonstrate that PLD2, but not PLD1, hPLD1 and mPLD2 constructs, S1P stimulated accumulation of regulates S1P-induced migration of HPAECs. PKC-⑀, but Not PKC-␨, Regulates S1P-induced PLD [32P]PBt. In vector-infected cells, S1P stimulated [32P]PBt accumulation by 2.5-fold (vehicle, 1164 ⫾ 76 dpm; S1P, 2588 ⫾ 132 Activation—Having established a role for PKC-⑀ and -␨ and dpm). Overexpression of hPLD1 (vehicle, 850 ⫾ 89 dpm; S1P, PLD2 in S1P-induced migration, we further characterized the 5061 ⫾ 280 dpm) or mPLD2 (vehicle, 896 ⫾ 74 dpm; S1P, signaling cascades of PKC-⑀ and -␨ in S1P-induced PLD activa7656 ⫾ 410 dpm) enhanced S1P-mediated [32P]PBt accumulation using peptide inhibitors. HPAECs were incubated with tion compared with vector controls (supplemental Fig. 3, C and PKC-⑀ peptide inhibitor (10 ␮M, 2 h) or myristoylated PKC-␨




11801


FIGURE 7. Effect of PLD2 siRNA on S1P-induced activation of PKC-⑀ and PKC-␨ in HPAECs. HPAECs grown to ⬃60% confluence in 35-mm dishes or glass coverslips were transfected with Gene Silencer reagent plus scrambled (sc) siRNA or Gene Silencer reagent plus PLD2 siRNA (50 nM) for 72 h as described under “Experimental Procedures.” In A and C, cells transfected with scrambled or PLD2 siRNA, as indicated above, were challenged with EBM-2 or EBM-2 containing S1P (1.0 ␮M) plus 0.1% BSA for 5 min, washed, fixed, permeabilized, and probed with anti-PKC-⑀ or PKC-␨ antibodies. Shown are representative immunofluorescence micrographs from three independent experiments. The redistribution of PKC-⑀ or PKC-␨ to cell periphery was quantified using an image analyzer as described under “Experimental Procedures.” Values are the mean ⫾ S.E. from three independent experiments and are expressed as relative pixels. In B, cells transfected with scrambled or PLD2 siRNA were challenged with S1P (1.0 ␮M) for 5 min, total cell lysates were subjected to immunoprecipitation (IP)with anti-PKC-⑀ antibody, and immunoprecipitates were assayed for PKC-⑀ activity with myelin basic protein as a substrate by Western blotting (WB) with anti-phosphoserine antibody. The results of S1P-induced phosphorylation of MBP by PKC-⑀ immunoprecipitates were calculated by densitometry. The values are the mean ⫾ S.E. for three independent experiments and are normalized to total PKC-⑀ in the immunoprecipitates. In D, cells transfected with scrambled or PLD2 siRNA were challenged with S1P (1.0 ␮M) for 5 min, total cell lysates (250 ␮g of total protein) were immunoprecipitated with anti-PKC-␨ antibody, and immunoprecipitates were separated by SDS-PAGE and Western blotted with anti-phospho-PKC-␨ and anti-PKC-␨ antibodies. The results of S1P-induced phosphorylation of PKC-␨ were calculated by densitometry. The values are the mean ⫾ S.E. for three independent experiments and are normalized to total PKC-␨ in the immunoprecipitates. N.S., not significant.

peptide (10 ␮M, 2 h). In parallel experiments, cells were labeled with [32P]orthophosphate overnight before stimulation with S1P for activation of PLD. Pretreatment of cells with either PKC-⑀ peptide inhibitor or myristoylated PKC-␨ peptide attenuated translocation of the respective isoform to cell periphery as determined by immunofluorescence microscopy (supplemental Fig. 4, A and B). Additionally, as shown in supplemental Fig. 4, C and D, the S1P stimulation of [32P]PBt formation by treatment with S1P for 5 min was blocked by dnPKC-⑀ and PKC-⑀ peptide inhibitor but not by dnPKC-␨ and myristoylated PKC-␨ peptide. These results demonstrate that S1P activated PKC-⑀ upstream of PLD and that PKC-␨ is downstream of PLD in HPAECs. PLD2 siRNA Attenuates S1P-induced PKC-␨, but Not PKC-⑀, Activation in HPAECs—To further characterize the role of PLD2 in S1P-induced PKC-␨ activation, HPAECs grown on glass coverslips or 35-mm dishes were transfected with PLD2 siRNA (50 nM) for 72 h, and cells were challenged with S1P for 5 min. Activation of PKC-⑀ and PKC-␨ was then determined by immunocytochemistry or Western blotting. S1P treatment stimulated translocation of PKC-⑀ and PKC-␨ isoforms to the plasma membrane (Fig. 7, A and C), and activation of PKC-⑀ and -␨ isoforms compared with control cells (Fig. 7, B and D). Similarly, knockdown of PLD2 with PLD2 siRNA blocked S1P-induced translocation and phosphorylation of PKC-␨, but not PKC-⑀ (Fig. 7, A–D). These results further establish that PLD regulates S1P-induced PKC-␨, but not PKC-⑀, activation in HPAECs. PLD2 Regulates S1P-induced HPAEC Migration via Rac1—Earlier studies demonstrated that Rac1 regulates S1P-induced EC migration (50); however, the role of PLD in Rac1 activation is largely unknown. Therefore, we characterized the link between PLD signaling and Rac1 activation in S1P-medi-


ated HPAEC migration. S1P (1 ␮M) activated translocation of Rac1 to cell plasma membrane in a time-dependent manner (Fig. 8A). Activation of Rac1 by S1P was also verified by immunoprecipitation of Rac1-GTP with PAK-1 PBD. S1P increased the activation of Rac1 with a peak at 2 min after S1P challenge (Fig. 8B). To demonstrate a role for Rac1 in cell migration,


DISCUSSION Migration of ECs is an important physiological process required for wound healing, repair of blood vessels, and angiogenesis during normal and also pathological conditions such as atherogenesis and balloon angioplasty. Several studies demonstrated a role for platelet-derived growth factor, vascular endothelial growth factor, and fibroblast growth factor as well as ECM-derived proteins such as fibronectin, vitronectin, collagen, and laminin in regulating EC migration and angiogenesis (25, 51). Recently, S1P was shown to be a potent EC migratory factor (26, 27, 52) that promotes wound healing; however, the signaling mechanisms of S1P-induced EC migration in the pulmonary endothelium are poorly defined. The present work employed both a wound healing and transendothelial electrical resistance assay that detects mainly chemokinesis to characterize signaling pathways regulating S1P-mediated migration of human lung ECs. Our novel findings are that (i) S1P activates both PKC-⑀ and -␨ isoforms in HPAECs, (ii) stimulation of PKC-⑀ by S1P, but not PKC-␨, activates PLD2, and (iii) activation of PLD2 by PKC-⑀ through S1P in turn stimulates migration via PKC-␨ and Rac1. Furthermore, we observed that S1P1 is the predominant S1P receptor expressed in HPAECs, which is coupled to Gi in transducing signals from S1P to intracellular targets such as PLD. S1P is a potent and pleotropic bioactive sphingolipid that mediates cellular responses such as proliferation, differentiation, tumor cell invasion, cell migration, and angiogenesis via G-protein-coupled S1P1–5 (7–9). Earlier studies showed that S1P regulates cell motility, and whether it is stimulatory or inhibitory depends upon the cell type and the expression of VOLUME 283 • NUMBER 17 • APRIL 25, 2008


FIGURE 8. Role of Rac1 in S1P-induced migration of HPAECs. HPAECs grown to ⬃90% confluence on glass coverslips, or 35-mm dishes were starved overnight in EBM-2 containing 0.1% FBS without any growth factors. In A, cells on coverslips were stimulated with EBM-2 or EBM-2 containing S1P (1.0 ␮M) plus 0.1% BSA for 2, 5, and 15 min, washed, fixed, permeabilized, probed with anti-Rac1 antibody, and examined by immunofluorescence microscopy using a ⫻60 oil objective. Translocation of Rac1 to cell periphery was semiquantified using an image analyzer as described under “Experimental Procedures.” The values are the mean ⫾ S.E. for three independent experiments. In B, activated Rac1 was immunoprecipitated (IP) from total cell lysates (500 ␮g of total protein) from control and S1P (1.0 ␮M)-treated cells using PAK-1 PBD-agarose beads as described under “Experimental Procedures.” Rac-1-GTP bound to PAK-1 PBD were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-Rac1 antibody. Shown is a representative blot from three independent experiments, and Rac1 activation was quantified from the Western blots (WB) by image analysis and normalized to total ␤-actin in the cell lysates. The values are the mean ⫾ S.E. from three independent experiments. In C, HPAECs grown to 80% confluence in 35-mm dishes were infected with empty vector or adenoviral vector containing cDNA for dnRac1 (1, 5, and 10 m.o.i.) in complete EGM-2 medium for 24 h. Cell lysates were subjected to SDS-PAGE and Western blotting with anti-Rac1 antibody. The cells were scratched for the migration assay and challenged with EBM-2 medium alone or medium containing S1P (1.0 ␮M) in the presence of 0.1% BSA. The migration of cells was recorded by imaging at 0 and 16 h after scratch, and the average area by which the gap between the ECs closed over 16 h was determined. The values are the mean ⫾ S.E. for three independent experiments in triplicate and expressed as % of control. In D, the cells transfected with scrambled (sc) or Rac1 siRNA and then challenged with S1P (1.0 ␮M) for 16 h as indicated in C. Total cell lysates were subjected to SDSPAGE and Western blotting with anti Rac1 antibody. The migration of cells was recorded by imaging at 0 and 16 h after scratch, and the average area by which the gap between the ECs closed over 16 h was determined. The values are the mean ⫾ S.E. for three independent experiments in triplicate and are expressed as % control.

HPAECs were infected with adenoviral dnRac1 (1–10 m.o.i.) for 48 h or transfected with Rac1 siRNA (50 nM) for 72 h. Although infection of HPAECs with the dnRac1 at varying multiplicities of infection for 24 h resulted in overexpression of the protein (Fig. 8C), knockdown of Rac1 with Rac1 siRNA downregulated Rac1 expression by ⬃85% (Fig. 8D). Furthermore, as shown in Fig. 8, C and D, dnRac1 or Rac1 siRNA significantly reduced S1P-induced closure of wound. Next, we investigated the role of PLD2 in S1P-induced Rac1 activation. HPAECs either on glass coverslips or 60-mm dishes were transfected with PLD2 siRNA (50 nM) for 72 h or infected with mPLD2-K758R mutant (10 m.o.i.) for 24 h. These treatments attenuated S1P-induced translocation of Rac1 to cell plasma membrane and decreased S1P-induced association of Rac1 with p21-activated protein (Fig. 9, A–D). These results demonstrate that PLD2 regulates S1P-induced activation of Rac1 in HPAECs. PKC-␨ Regulates S1P-induced Rac1 Activation—Having established a role for PLD2 in PKC ␨ and Rac1 activation by S1P, we determined the role of PKC-␨ in Rac1 stimulation. HPAECs were pretreated with myristoylated PKC-␨ peptide (10 ␮M) for 2 h before S1P challenge. As shown in Fig. 10, A and B, myristoylated PKC-␨ peptide attenuated S1P-induced phosphorylation of PKC-␨ and S1P-mediated translocation of Rac1 to cell plasma membrane, respectively. These results demonstrate that PKC-␨ regulates S1P-induced Rac1 activation in HPAECs.




11803


FIGURE 9. Knockdown of PLD2 blocks S1P-induced Rac1 activation in HPAECs. In A and B, HPAECs grown to ⬃50% confluence on glass coverslips or 35-mm dishes and were transfected with scrambled (sc, 50 nM) or PLD2 siRNA (50 nM) for 72 h. In A, cells were challenged with EBM-2 plus 0.1% BSA or EBM-2 plus 0.1% BSA containing S1P (1.0 ␮M) for 5 min, washed, fixed, permeabilized, and probed with anti-Rac1 antibody. Translocation of Rac1 to cell periphery was quantified using an image analyzer as described under “Experimental Procedures.” The values are the mean ⫾ S.E. for three independent experiments. Veh, vehicle. B shows Western blot (WB) analysis and quantification of Rac1 activation by S1P, as determined by PAK-1 PBD assay in scrambled and PLD2 siRNA-transfected HPAECs. The values are the mean ⫾ S.E. for three independent experiments normalized to total ␤-actin. IP, immunoprecipitation. In C, HPAECs (⬃80% confluence on glass coverslips) were infected with empty vector or adenoviral vectors containing cDNA for mPLD2 mutant (mu, K758R) (10 m.o.i.) in complete EGM-2 medium for 24 h. Cells were challenged with EBM-2 plus 0.1% BSA or EBM-2 plus 0.1% BSA containing S1P (1.0 ␮M) for 5 min, fixed as indicated above, and probed with anti-Rac1 antibody. Shown is a representative immunofluorescence micrograph from three independent experiments. Translocation of Rac1 to cell periphery was quantified using an image analyzer as described under “Experimental Procedures.” The values are the mean ⫾ S.E. for three independent experiments. In D, cell lysates (500 ␮g of total protein) from empty vector and mPLD2 mutant-infected cells, as described for C, were immunoprecipitated with PAK-1 PBD-agarose, and immunoprecipitates were subjected to SDS-PAGE and Western blotting with anti-Rac1 antibody. Activation of Rac1 was quantified by image analysis and normalized to ␤-actin in total cell lysates. The values are the mean ⫾ S.E. for three independent experiments. N.S., not significant.

different S1P-receptors. Although S1P stimulates migration of ECs (26, 27), it inhibited chemotactic cell motility of several tumor cell lines (53, 54) and vascular smooth muscle cells (55, 56). S1P induces EC migration and angiogenesis in human umbilical vein (2) and bovine aortic ECs (26) that require the expression of S1P1 and S1P3 (2, 10, 12). The S1P-mediated migration of human umbilical vein ECs was sensitive to C3 exotoxin (10), and PTx (27, 28) and required activation of integrin ␣v␤3 via Rho, but not Rac (10). Furthermore, in one study PKC inhibitor showed no effect on S1Pinduced migration of human umbilical vein ECs, but inhibition of phospholipase C abrogated the S1P response (57). Although vascular endothelial growth factorstimulated migration and proliferation of ECs was dependent on the nitric oxide-mediated decrease in PKC-␦ activity (58), sustained PKC-␦ activation by lysophosphatidylcholine also inhibited syndecan-4-dependent assembly/ disassembly of focal adhesions necessary for migration of bovine aortic ECs (59). In the present study we demonstrated a role for PKC-⑀ and -␨, but not -␣ and -␦, isoforms in S1P-induced migration of HPAECs using overexpression of dnPKC isoforms and peptide inhibitors. Our results show that dnPKC-⑀ and PKC-⑀ peptide inhibitor, but not dnPKC-␨ or myristoylated PKC-␨ peptide, attenuated S1P-induced PLD activation in HPAECs. We observed some variation in the control levels of cell migration from ⬃25% (Figs. 1 and 2A and 6B) to ⬃50% (supplemental Figs. 2 and 4) when we used different batches of primary HPAECs. This variation can be attributed to differences in responses from individual donors. Nevertheless, our results consistently demonstrate distinct roles for PKC-⑀ and -␨ in S1P-induced cell migration, and we show for the first time that S1P-mediated stimulation of PLD2 is regulated by PKC-⑀, whereas PKC-␨ activation is downstream of PLD2.





of PKC-␨ is yet to be defined. PKC-␨ is insensitive to diacylglycerol and Ca2⫹ (36, 63), but it can be activated by acidic lipids such as PA, phosphatidylinositol, and phosphatidylinositol 3,4,5-trisphosphate (64). Although PA can physically bind to and activate PKC-␨ in vitro and in vivo (38, 39, 65), it is unclear if PKC-␨ has any domain structure for PA binding. It has been reported that Rac-associated type I phosphatidylinositol-4-phosphate 5-kinase (PIP5K), but not type II PIP5K, is stimulated by PA (66). It is possible that stimulation of type I phosphatidylinositol-4-phosphate 5-kinase by PA in cells results in enhanced phosphatidylinositol-4,5-bisphosphate generation, which is phosFIGURE 10. Inhibition of S1P-induced Rac1 activation by myristoylated PKC-␨ peptide in HPAECs. In A, phorylated by phosphatidylinositol HPAECs grown on 35-mm dishes (⬃90% confluence) were pretreated with myristoylated PKC-␨ peptide (10 3-kinase to form phosphatidylinosi␮M) for 2 h before S1P (1.0 ␮M) challenge for 5 min. Cell lysates from control and S1P-treated cells (500 ␮g of tol 3,4,5-trisphosphate. It is of interprotein) were subjected to immunoprecipitation with anti-PKC-␨ antibody, and immunoprecipitates were separated by SDS-PAGE, probed with anti-phospho (p) PKC-␨ and anti-PKC-␨ antibodies, and quantified by est that regulators of PLD1, namely image analysis. Shown is a representative Western blot (WB) from three independent experiments. The values RalA and Arf6 (67, 68), are implifor phosphorylation of PKC-␨ are the mean ⫾ S.E. from three independent experiments and are normalized to cated in cell migration. The formatotal PKC-␨ in the immunoprecipitates. In B, HPAECs grown on glass coverslips (⬃90% confluence) were pretreated with PKC-␨-myristoylated peptide (10 ␮M) for 2 h and then challenged with S1P (1.0 ␮M) for 5 min. Cells tion of stress fibers is linked to were washed, fixed, permeabilized, and probed with anti-Rac1 antibody. A representative immunofluores- migration, and PLD activity incence micrograph from three independent experiments is shown. Quantification of Rac1 translocation was performed using image analysis software, and values are the mean ⫾ S.E. from three independent experi- creases stress fiber formation (69). ments. Veh, vehicle. Thus, factors that regulate PLD activity and responses to PLD sigWe demonstrated earlier that S1P stimulated PLD1 and nals co-ordinate and support cell motility in a variety of normal PLD2 activity in Beas-2B bronchial epithelial cells (22). In and cancer cells. Interestingly, our results show Rac1 is part of HPAECs, the S1P-induced PLD activation was PTx-sensitive signaling cascade involved in S1P-mediated cell migration, and and was blocked by SB649146 and S1P1 siRNA, demonstrating PLD2 regulates Rac1 activation via PKC-␨ in HPAECs. In addithe involvement of S1P1 coupled to Gi. Furthermore, the par- tion to Rac1, infection of HPAECs with dn Cdc42 or Rho (5 ticipation of PLD2, but not PLD1, in S1P-induced cell migra- m.o.i.) partially reduced S1P-induced cell migration, confirmtion was established by expression of mPLD2-K758R and ing a role for these Rho family of GTPases in migration. Rac1 siRNA for PLD2 that blocked S1P-induced cell migration. By transduces signals from agonists to induce changes in cell contrast, infection of cells with hPLD1-K898R or PLD1 siRNA motility, cytoskeletal organization, cell morphology, and adhehad no effect on S1P-dependent cell migration. These results sion. Although several earlier studies showed that growth facprovide the first direct evidence for the participation of PLD2, tors such as vascular endothelial growth factor and nerve but not PLD1, in S1P-induced EC migration. This work sup- growth factor caused Rac1 stimulated lamellipodia formation ports earlier studies with rat fibroblasts that showed a role for and cell migration (70, 71), the signaling pathway(s) of S1PPLD2, but not PLD1, in LPA-induced migration (32). A poten- mediated Rac1 activation has been not studied. S1P-stimulated tial explanation for this differential participation by PLD could Rac1 activation is linked to cytoskeletal organization and barbe differences in the subcellular localization of PLD1 and PLD2 rier regulation of human lung ECs (72). In this study we identiin mammalian cells. PLD1 is localized in the cytosol, Golgi fied PKC-␨ as a downstream target of PLD2 in mediating S1P apparatus, nucleus, and plasma membrane, whereas PLD2 is signaling to Rac1 in HPAECs. Our current results on PLD2-deprimarily found in the plasma membrane (41, 60, 61). pendent activation of Rac1 are in contrast to an earlier report A role for PLD and PA generated via PLD has been impli- on Rac1-dependent regulation of PLD1b by antigens in RBLcated in the secretion of proinflammatory cytokines (22), acti- 2H3 cells (73). Furthermore, we observed that dnRac1 or Rac1 vation of phagocytic NADPH oxidase (34), and regulation of siRNA had no effect on S1P-induced PLD activation, transloneutrophil/fibroblast/cancer cell migration (33, 62). It is not cation of PKC-⑀ and PKC-␨ to cell periphery, and transient clear how PA generated by either PLD1 or PLD2 activation increase of [Ca2⫹]i, further confirming that Rac1 is downregulates cell migration. Our studies show for the first time that stream to PLD, PKC-⑀/PKC-␨ activation, and changes in intraPLD regulates Rac1 via PKC-␨ and cell migration in HPAECs; cellular Ca2⫹ (results not shown). Thus, Rac1 is not a prerequihowever, the mechanism(s) of PLD/PA-dependent activation site for initiation of S1P signaling via S1P1/Gi in HPAECs.


Acknowledgments—We thank Dr. C. E. Chalfant from the Virginia Commonwealth University School of Medicine (Richmond, VA) for the C18:1 ceramide 1-phosphate and Dr. Motoi Ohba from the Institute of Molecular Oncology (Showa University, Japan) for kindly providing aliquots of adenoviral constructs of vector and dominant negative PKC␣, -␦, -⑀, -␨, and -␭ isoforms. We thank the services of the University of Iowa Gene Transfer Vector Core, supported in part by the National Institutes of Health and Roy J. Carver Foundation, for viral amplification and generation of purified dominant negative PKC isoform adenoviral constructs.

4

I. Gorshkova and V. Natarajan, unpublished results.


REFERENCES 1. Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155–167 2. Lee, M. J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha’afi, R. I., and Hla, T. (1999) Cell 99, 301–312 3. Pyne, S., and Pyne, N. (2000) Pharmacol. Ther. 88, 115–131 4. Kluk, M. J., and Hla, T. (2001) Circ. Res. 89, 496 –502 5. Ozaki, H., Hla, T., and Lee, M. J. (2003) J. Atheroscler. Thromb. 10, 125–131 6. Spiegel, S., and Milstien, S. (2003) Biochem. Soc. Trans. 31, 1216 –1219 7. Pyne, S., and Pyne, N. J. (2000) Biochem. J., 349, 385– 402 8. Spiegel, S., and Milstien, S. (2002) J. Biol. Chem. 277, 25851–25854 9. Sanchez, T., and Hla, T. (2004) J. Cell. Biochem. 92, 913–922 10. Paik, J. H., Chae, S. S., Lee, M. J., Thangada, S., and Hla, T. (2001) J. Biol. Chem. 276, 11830 –11837 11. Garcia, J. G., Liu, F., Verin, A. D., Birukova, A., Dechert, M. A., Gerthoffer, W. T., Bamberg, J. R., and English, D. (2001) J. Clin. Investig. 108, 689 –701 12. Donati, C., and Bruni, P. (2006) Biochim. Biophys. Acta 1758, 2037–2048 13. Banno, Y., Takuwa, Y., Akao, Y., Okamoto, H., Osawa, Y., Naganawa, T., Nakashima, S., Suh, P. G., and Nozawa, Y. (2001) J. Biol. Chem. 276, 35622–35628 14. Pyne, N. J., Waters, C., Moughal, N. A., Sambi, B. S., and Pyne, S. (2003) Biochem. Soc. Trans. 31, 1220 –1225 15. Long, J. S., Natarajan, V., Tigyi, G., Pyne, S., and Pyne, N. J. (2006) Prostaglandins Other Lipid Mediat. 80, 74 –78 16. Okamoto, H., Takuwa, N., Yokomizo, T., Sugimoto, N., Sakurada, S., Shigematsu, H., and Takuwa, Y. (2000) Mol. Cell. Biol. 20, 9247–9261 17. Kon, J., Sato, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) J. Biol. Chem. 274, 23940 –23947 18. Gonda, K., Okamoto, H., Takuwa, N., Yatomi, Y., Okazaki, H., Sakurai, T., Kimura, S., Sillard, R., Harii, K., and Takuwa, Y. (1999) Biochem. J. 337, 67–75 19. Gra¨ler, M. H., Grosse, R., Kusch, A., Kremmer, E., Gudermann, T., and Lipp, M. (2003) J. Cell. Biochem. 89, 507–519 20. Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M. S., Calver, A. R., Duddy, G., Walsh, F. S., Pangalos, M. N., Arimura, N., Kaibuchi, K., Zalc, B., and Lubetzki, C. (2005) J. Neurosci. 25, 1459 –1469 21. Michel, M. C., Mulders, A. C., Jongsma, M., Alewijnse, A. E., and Peters, S. L. (2007) Acta Paediatr. Suppl. 96, 44 – 48 22. Cummings, R. J., Parinandi, N. L., Zaiman, A., Wang, L., Usatyuk, P. V., Garcia, J. G., and Natarajan, V. (2002) J. Biol. Chem. 277, 30227–30235 23. Schwartz, B. M., Hong, G., Morrison, B. H., Wu, W., Baudhuin, L. M., Xiao, Y. J., Mok, S. C., and Xu, Y. (2001) Gynecol. Oncol. 81, 291–300 24. Kono, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M. L., Wu, Y. P., Yamashita, T., and Proia, R. L. (2004) J. Biol. Chem. 279, 29367–29373 25. Lamalice, L., Le Boeuf, F., and Huot, J. (2007) Circ. Res. 100, 782–794 26. Panetti, T. S., Nowlen, J., and Mosher, D. F. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 1013–1019 27. Lee, H., Goetzl, E. J., and An, S. (2000) Am. J. Physiol. Cell Physiol. 278, 612– 618 28. English, D., Welch, Z., Kovala, A. T., Harvey, K., Volpert, O. V., Brindley, D. N., and Garcia, J. G. (2002) FASEB J. 14, 2255–2265 29. Lee, M. J., Thangada, S., Paik, J. H., Sapkota, G. P., Ancellin, N., Chae, S. S., Wu, M., Morales-Ruiz, M., Sessa, W. C., Alessi, D. R., and Hla, T. (2001) Mol. Cell 8, 693–704 30. Li, Y., Uruno, T., Haudenschild, C., Dudek, S. M., Garcia, J. G., and Zhan, X. (2004) Exp. Cell Res. 298, 107–121 31. Alvarez, S. E., Milstien, S., and Spiegel, S. (2007) Trends Endocrinol. Metab. 18, 300 –307 32. Wang, L., Cummings, R., Usatyuk, P., Morris, A., Irani, K., and Natarajan, V. (2002) Biochem. J. 367, 751–760 33. Pilquil, C., Dewald, J., Cherney, A., Gorshkova, I., Tigyi, G., English, D., Natarajan, V., and Brindley, D. N. (2006) J. Biol. Chem. 281, 38418 –38429 34. Cummings, R., Parinandi, N., Wang, L., Usatyuk, P., and Natarajan, V. (2002) Mol. Cell. Biochem. 234 –235, 99 –109 35. Cross, M. J., Roberts, S., Ridley, A. J., Hodgkin, M. N., Stewart, A.,


11805


Furthermore, S1P-induced transient [Ca2⫹]i was sensitive to PTx (⬃85% inhibition) and SB649146 (⬃80% inhibition) treatment, suggesting participation of S1P1 linked to Gi in the response (results not shown). Although, we have not studied the essential role of [Ca2⫹]i in endothelial cell motility, studies carried out in HUVECs indicate that [Ca2⫹]i signal is linked to S1P-induced cell migration via tyrosine phosphorylation of focal adhesion kinase (2, 57). S1P-induced cell migration is not completely attenuated by blocking PLD2 with catalytically inactive mutant/siRNA (Figs. 5B and 6B), which may reflect an incomplete inhibition of PLD2. However, we predict that additional pathways independent of PLD2 might be involved in mediating cell motility in HPAECs. For example, in HPAECs S1P also promotes Tiam1/ Rac1 activation via phosphatidylinositol 3-kinase (PI3K) (74), suggesting a potential role for PI3K signaling in cell motility. Earlier, we demonstrated a role for phosphatidylinositol 3-kinase (PI3K) in S1P-induced EC migration (75); however, it is unclear if PI3K signals via PKC-␨ and/or Rac1 in cell migration. Interestingly, blocking phosphatidylinositol 3-kinase with LY294002 (1–25 ␮M) did not attenuate S1P-induced PLD activation, indicating the absence of phosphatidylinositol 3-kinasedependent activation of PLD signaling by S1P in HPAECs.4 Furthermore, specific guanine nucleotide exchange factors couple growth factor signaling to the Rho family of GTPases (71, 76). The effect of vascular endothelial growth factor on Rac1-dependent motility of human umbilical vein ECs is regulated by Vav2 guanine nucleotide exchange factor (GEF) (69), and our preliminary results show that S1P-induced Rac1 activation is partly dependent on Tiam1, another GEF for Rac1.4 However, the role of Tiam1 in PLD2-dependent regulation of Rac1 via PKC-␨ is unclear, and future studies will address the role of guanine nucleotide exchange factors in S1P-induced cell motility. S1P is a natural component of plasma and is present in nM to ␮M levels (7, 46). Although stimulation of human lung EC migration by S1P is important for normal blood vessel function, S1P also stimulates neovascularization and tumor cell metastasis. Precise understanding of S1P-mediated signaling is important in developing novel therapeutic agents against targets regulating EC motility. Our identification of PKC-⑀ as an activator of PLD2 regulating S1P-induced migration and coupling PLD2 to Rac1 via PKC-␨ indicates that PKC-⑀ and PLD2 could be potential targets for inhibiting excessive angiogenesis.



57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76.

Kovala, A. T., McGlynn, P., Brindley, D. N., Rhoades, R. A., and English, D. (2002) Exp. Cell Res. 274, 264 –274 Lee, O.-H., Lee, D.-J., Kim, Y.-M., Kim, Y. S., Kwon, H. J., Kim, K.-W., and Kwon, Y.-G. (2000) Biochem. Biophys. Res. Commun. 268, 47–53 Shizukuda, Y., Tang, S., Yokota, R., and Ware, J. A. (1999) Circ. Res. 85, 247–256 Chaudhuri, P., Colles, S. M., Fox, P. L., and Graham, L. M. (2005) Circ. Res. 97, 674 – 681 Freyberg, Z., Sweeney, D., Siddhanta, A., Bourgoin, S., Frohman, M., and Shields, D. (2001) Mol. Biol. Cell 12, 943–955 Du, G., Huang, P., Liang, B. T., and Frohman, M. A. (2004) Mol. Biol. Cell 15, 1024 –1030 Lehman, N., Di Fulvio, M., McCray, N., Campos, I., Tabatabaian, F., and Gomez-Cambronero, J. (2006) Blood 108, 3564 –3572 Ohno, S., and Nishizuka, Y. (2002) J. Biochem. (Tokyo) 132, 509 –511 Hirai, T., and Chida, K. (2003) J. Biochem. (Tokyo) 133, 1–7 Kanaho, Y., Nakayama, K., Frohman, M. A., and Yokozeki, T. (2007) Methods Enzymol. 434, 155–169 Tolias, K. F., Couvillon, A. D., Cantley, L. C., and Carpenter, C. L. (1998) Mol. Cell. Biol. 18, 762–770 Kim, J. H., Lee, S. D., Han, J. M., Lee, T. G., Kim, Y., Park, J. B., Lambeth, J. D., Suh, P. G., and Ryu, S. H. (1998) FEBS Lett. 430, 231–235 Santy, L. C., and Casanova, J. E. (2001) J. Cell Biol. 154, 599 – 610 Porcelli, A. M., Ghelli, A., Hrelia, S., and Rugolo, M. (2002) Cell. Signal. 14, 75– 81 Yasui, H., Katoh, H., Yamaguchi, Y., Aoki, J., Fujita, H., Mori, K., and Negishi, M. (2001) J. Biol. Chem. 276, 15298 –15305 Garrett, T. A., Van Buul, J. D., and Burridge, K. (2007) Exp. Cell Res. 313, 3285–3297 Shikata, Y., Birukov, K. G., and Garcia, J. G. (2003) J. Appl. Physiol. 94, 1193–1203 Powner, D. J., Hodgkin, M. N., and Wakelam, M. J. (2002) Mol. Biol. Cell 13, 1252–1262 Singleton, P. A., Dudek, S. M., Chiang, E. T., and Garcia, J. G. (2005) FASEB J. 19, 1646 –1656 Gorshkova, I. A., Berdyshev, E. V., Saatian, B., Garcia, J. G. N., and Natarajan, V. (2005) FASEB J. 19, (Abstr. 282) Overbeck, A. F., Brtva, T. R., Cox, A. D., Graham, S. M., Huff, S. Y., Khosravi-Far, R., Quilliam, L. A., Solski, P. A., and Der, C. J. (1995) Mol. Reprod. Dev. 42, 468 – 476



Claesson-Welsh, L., and Wakelam, M. J. (1996) Curr. Biol. 6, 588 –597 36. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K, and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3099 –3103 37. Stasek, J. E., Jr., Natarajan, V., and Garcia, J. G. (1993) Biochem. Biophys. Res. Commun. 191, 1341–1341 38. Limatola, C., Schaap, D., Moolenaar, W. H., and van Blitterswijk, W. J. (1994) Biochem. J. 304, 1001–1008 39. Moritz, A., De Graan, P. N., Gispen, W. H., and Wirtz, K. W. (1992) J. Biol. Chem. 267, 7207–7210 40. Jenkins, G. H., Fisette, P. L., and Anderson, R. A. (1994) J. Biol. Chem. 269, 11547–11554 41. Jenkins, G. M., and Frohman, M. A. (2005) Cell. Mol. Life Sci. 62, 2305–2316 42. Jones, G. A., and Carpenter, G. (1993) J. Biol. Chem. 268, 20845–20850 43. Cockcroft, S. (2001) Cell. Mol. Life Sci. 58, 1674 –1687 44. Delon, C., Manifava, M., Wood, E., Thompson, D., Krugmann, S., Pyne, S., and Ktistakis, N. T. (2004) J. Biol. Chem. 279, 44763– 44774 45. Kishikawa, K., Chalfant, C. E., Perry, D. K., Bielawska, A., and Hannun, Y. A. (1999) J. Biol. Chem. 274, 21335–21341 46. Zhao, Y., Kalari, S. K., Usatyuk, P. V., Gorshkova, I., He, D., Watkins, T., Brindley, D. N., Sun, C., Bittman, R., Garcia, J. G., Berdyshev, E. V., and Natarajan, V. (2007) J. Biol. Chem. 282, 14165–14177 47. Usatyuk, P. V., Parinandi, N. L., and Natarajan, V. (2006) J. Biol. Chem. 281, 35554 –35566 48. Waters, C. M., Long, J., Gorshkova, I., Fujiwara, Y., Connell, M., Belmonte, K. E., Tigyi, G., Natarajan, V., Pyne, S., and Pyne, N. J. (2006) FASEB J. 20, 509 –511 49. Thompson, B., Ancellin, N., Fernandez, S. M., Hla, T., and Sha’afi, R. I. (2006) Prostaglandins Other Lipid Mediat. 80, 15–27 50. Li, Z., Paik, J. H., Wang, Z., Hla, T., and Wu, D. (2005) Prostaglandins Other Lipid Mediat. 76, 95–104 51. Davis, G. E., and Senger, D. R. (2005) Circ. Res. 97, 1093–1107 52. English, D., Kovala, A. T., Welch, Z., Harvey, K. A., Siddiqui, R. A., Brindley, D. N., and Garcia, J. G. (1999) J. Hematother. Stem Cell Res. 8, 627– 634 53. Sadahira, Y., Ruan, F., Hakomori, S., and Igarashi, Y. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9686 –9690 54. Wang, F., Nohara, K., Olivera, A., Thompson, E. W., and Spiegel, S. (1999) Exp. Cell Res. 247, 17–28 55. Ryu, Y., Takuwa, N., Sugimoto, N., Sakurada, S., Usui, S., Okamoto, H., Matsui, O., and Takuwa, Y. (2002) Circ. Res. 90, 325–332 56. Boguslawski, G., Grogg, J. R., Welch, Z., Ciechanowicz, S., Sliva, D.,